Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood markers may forecast preterm delivery within a week

NCT ID NCT01340222

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 210 pregnant women hospitalized for preterm labor between 24 and 34 weeks. Researchers measured specific immune cells in their blood to see if these could predict whether they would deliver within 7 days. The goal is to find a more accurate way to identify women at highest risk, improving care and reducing unnecessary interventions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

210 people

The number who actually took part.

Started

Mar 2011

Finished

Jul 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients: * Threat of preterm labour (PTL) occurring between 24 and 34 WOA, defined according to validated criteria i.e. by (1) the presence of regular uterine contractions, lasting at least 30 seconds at a frequency ≥ 4 contractions every 30 minutes and confirmed by an external tocogram, (2) a cervical dilation of 3 cm or greater, to focus on true preterm labour, for the nulliparous women and 1-3 cm among primiparous women or multiparous and (3) a cervical obliteration \>50%, or a cervix less than 25mm according to the echography, when this information is available. The first two criteria being mandatory, the third one optional as it is more subjective, or less likely to be available for every patient. * Person who has given written consent * Singleton pregnancy Inclusion Criteria for volunteers: * Person who has given written consent * Group 1: Women of reproductive age who have never had a pregnancy, even if not completed to term. * Group 2: Single full-term, uncomplicated pregnancy (= out of hospital) older than 6 months. Exclusion Criteria for patients: * Pre-existing diabetes or gestational diabetes, morbid obesity (BMI \> 35 kg/m2) as these situations modify the expression of MCP-1. * Woman presenting a spontaneous rupture of membranes (SRM) with confirmed or probable chorioamniotitis * Inflammatory or auto-immune disease * Suspected or confirmed infectious disease, including HIV, HCV, HBV * Anti-inflammatory drug treatment or immuno-modulator. * Multiple pregnancies * PTL \<24 WOA or \>34 WOA * Patient less than 18 years of age. * Patient not affiliated to social security insurance Exclusion Criteria for volunteers: * Pre-existing diabètes * Morbid obesity (BMI \> 35 kg/m2) * Inflammatory or auto-immune disease * Suspected or confirmed infectious disease, including HIV, HCV, HBV * Anti-inflammatory drug treatment or immuno-modulator. * Minor person * Person not affiliated to social security insurance * History of twin pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preterm labour are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obstetric Labor, Premature

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre d'investigation clinique plurithématique

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.